LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

Home・Aandelen Lijst・Takeda Pharmaceutical Co Ltd ADR

Takeda Pharmaceutical Co Ltd ADR

Gesloten

SectorGezondheidszorg

16.7 1.03

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

16.53

Max

16.75

Belangrijke statistieken
By Trading Economics
Inkomsten	117B 106B
Verkoop	100B 1.2T
K/W Sectorgemiddelde	75.273 49.8
EPS	0.21
Dividendrendement	3.98
Winstmarge	8.697
Werknemers	47,455
EBITDA	140B 456B

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+26.81% upside

Dividenden
By Dow Jones
Dividendrendement Sectorgemiddelde	3.98% 2.25%

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-3B 52B
Vorige openingsprijs	15.67
Vorige sluitingsprijs	16.7

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

N/A / 15.16 Steun & Weerstand

Takeda Pharmaceutical Co Ltd ADR Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

29 jan 2026, 07:11 UTC

Winsten

Takeda Posts Sharply Higher Quarterly Profit, Raises Annual Guidance

19 dec 2025, 03:32 UTC

Belangrijke Marktbewegers

Takeda Pharmaceuticals Shares Rise on Positive Psoriasis Treatment Results

30 okt 2025, 09:39 UTC

Winsten

Takeda Swings to Loss on Impairment Charges, Cuts Guidance -- Update

30 okt 2025, 07:32 UTC

Winsten

Takeda Posts Quarterly Net Loss, Cuts Guidance

21 okt 2025, 15:33 UTC

Belangrijke Marktbewegers

Healwell AI Shares Rise on AI-Platform Demonstration

29 jan 2026, 06:53 UTC

Winsten

Takeda Says Higher FY Revenue Forecast Due to Weaker Yen

29 jan 2026, 06:36 UTC

Winsten

Takeda Raises FY Revenue, Net-Profit Views

29 jan 2026, 06:34 UTC

Winsten

Takeda 3Q Net Profit Missed Y107.9B Expected in Poll of Analysts by Visible Alpha

29 jan 2026, 06:33 UTC

Winsten

Takeda Pharmaceutical 3Q Rev Y1.192T Vs. Y1.144T >4502.TO

29 jan 2026, 06:32 UTC

Winsten

Takeda Pharmaceutical 3Q Net Y103.6B Vs. Net Y23.8B >4502.TO

29 jan 2026, 06:30 UTC

Winsten

Takeda Pharmaceutical 9-Mos Net Y216.08B Vs Net Y211.08B

29 jan 2026, 06:30 UTC

Winsten

Takeda Pharmaceutical 9-Mos Pretax Pft Y312.67B Vs Pft Y282.38B

29 jan 2026, 06:30 UTC

Winsten

Takeda Pharmaceutical 9-Mos Oper Pft Y422.38B Vs Pft Y417.52B

29 jan 2026, 06:30 UTC

Winsten

Takeda Pharmaceutical 9-Mos Net Y216.08B Vs Net Y211.08B

29 jan 2026, 06:30 UTC

Winsten

Takeda Pharmaceutical 9-Mos Rev Y3.41T Vs Y3.53T

29 jan 2026, 06:30 UTC

Winsten

Takeda Pharmaceutical 9-Mos EPS Y137.31 Vs EPS Y133.71

30 okt 2025, 07:10 UTC

Winsten

Takeda: 1H Core Business Results Were Consistent With Company's Expectations

30 okt 2025, 06:50 UTC

Winsten

Takeda 2Q Net Loss Missed Y65.2B Profit Expected in Visible Alpha Poll of Analysts

30 okt 2025, 06:49 UTC

Winsten

Takeda Pharmaceutical 2Q Rev Y1.113T Vs. Y1.176T >4502.TO

30 okt 2025, 06:48 UTC

Winsten

Takeda Pharmaceutical 2Q Loss Y11.8B Vs. Net Y92.0B >4502.TO

30 okt 2025, 06:45 UTC

Winsten

Takeda: Lowered Guidance Reflects Impairment Charges Associated With Strategic Pipeline Decisions

30 okt 2025, 06:42 UTC

Winsten

Takeda Pharmaceutical Cuts FY Revenue, Net-Profit Views

30 okt 2025, 06:40 UTC

Winsten

Takeda Pharmaceutical 1H Net Y112.44B Vs Net Y187.29B

30 okt 2025, 06:40 UTC

Winsten

Takeda Pharmaceutical 1H Net Y112.44B Vs Net Y187.29B

30 okt 2025, 06:40 UTC

Winsten

Takeda Pharmaceutical 1H Pretax Pft Y178.80B Vs Pft Y255.98B

30 okt 2025, 06:40 UTC

Winsten

Takeda Pharmaceutical 1H EPS Y71.57 Vs EPS Y118.85

30 okt 2025, 06:40 UTC

Winsten

Takeda Pharmaceutical 1H Oper Pft Y253.56B Vs Pft Y350.58B

30 okt 2025, 06:40 UTC

Winsten

Takeda Pharmaceutical 1H Rev Y2.22T Vs Y2.38T

10 okt 2025, 15:13 UTC

Acquisities, Fusies, Overnames

J&J, Protagonist Have Existing Ties -- WSJ

10 okt 2025, 15:13 UTC

Acquisities, Fusies, Overnames

Protagonist Has Market Value Over $4B -- WSJ

Peer Vergelijking

Prijswijziging

Takeda Pharmaceutical Co Ltd ADR Prognose

Koersdoel

By TipRanks

26.81% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 21 USD 26.81%

Hoogste 21 USD

Laagste 21 USD

Gebaseerd op 1 Wall Street-analisten die 12-maands prijsdoelen bieden voor Takeda Pharmaceutical Co Ltd ADR - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

1 ratings

Buy

Hold

Sell

Gebaseerd op 1 analisten die aandelenratings hebben gegeven aan Takeda Pharmaceutical Co Ltd ADR - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

N/A / 15.16Steun & Weerstand

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

All events are bullish.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Takeda Pharmaceutical Co Ltd ADR

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.